HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lice “Smothering” Agents Should Be Explored, Researchers Assert

This article was originally published in The Tan Sheet

Executive Summary

Further research on topical agents that can asphyxiate lice should be conducted to enhance current treatment methods, according to a commentary published in the April issue of the Journal of the American Academy of Dermatology

You may also be interested in...

Rx pediculicide

Summers Laboratories is actively enrolling patients in a Phase III clinical trial for its patented lice asphyxiator product, tentatively named Lice Choker, the company announces April 24. An NDA for sale of the product as an Rx drug will be filed in the fourth quarter of 2006. The product contains "a simple mixture of ingredients currently used in other dermatological medications and cosmetics" and will suffocate lice more successfully than olive oil and petroleum jelly, Summers maintains. According to studies, two 10-minute applications of the product one week apart effectively kill all lice, the company states, with one study showing a 100% effective kill rate. A recent article in the Journal of the American Academy of Dermatology said asphyxiating treatments should be further researched, given the increasing resistance of lice to OTC pyrethroid-based formulas (1"The Tan Sheet" April 17, 2006, p. 13)...

Developmental Lice Lotion Could Make Pediculicide Marketers Itch

A head lice lotion that suffocates the insects cured 97% of children who used the treatment on the first try, according to a study in the September issue of Pediatrics

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts